Selective serotonin reuptake inhibitors and risk for major congenital anomalies

Obstetrics and Gynecology

Volumn 118, Issue 1, 2011, Pages 111-120

  Malm, Heli ^a,b,c,d   Artama, Miia ^a,b,c,d   Gissler, Mika ^a,b,c,d   Ritvanen, Annukka ^a,b,c,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANENCEPHALUS; AORTA VALVE STENOSIS; ARTICLE; CLEFT LIP; CLEFT LIP PALATE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; ENCEPHALOCELE; FALLOT TETRALOGY; FEMALE; FETAL ALCOHOL SYNDROME; FETUS; FIRST TRIMESTER PREGNANCY; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE DOUBLE OUTLET; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LIMB DEFECT; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; OMPHALOCELE; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PROGENY; PULMONARY VALVE ATRESIA; PULMONARY VALVE STENOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SPINA BIFIDA;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ALCOHOL DRINKING; FEMALE; FINLAND; FLUOXETINE; HEART SEPTAL DEFECTS, VENTRICULAR; HUMANS; MIDDLE AGED; PAROXETINE; PREGNANCY; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; YOUNG ADULT;

EID: 79959663476     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318220edcc     Document Type: Article

References (39)

1. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010;30:249-60.
2. Burt VK, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63:9-15. (Pubitemid 34454034)
3. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198: 194.e1-5.
4. Wichman CL, Moore KM, Lang TR, St. Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84:23-7.
5. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
6. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reup-take inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
7. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92. (Pubitemid 47001036)
8. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356: 2675-83. (Pubitemid 47001035)
9. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT. First trimester use of paroxetine and congenital heart defects: a population based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88:94-100.
10. Reis M, Kä llén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
11. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-70.
12. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26. (Pubitemid 47223423)
13. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85. (Pubitemid 350020060)
14. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96. (Pubitemid 41668948)
15. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76. (Pubitemid 351317794)
16. Bérard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol 2010;88:171-4.
17. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6.
18. Merlob P, Birk E, Sirota L, Linder N, Berant M, Stahl B, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009;85: 837-41.
19. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165:749-52. (Pubitemid 351810544)
20. Bérard A, Ramos E, Rey E, Blais L, St.-André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
21. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16:1086-94. (Pubitemid 350020061)
22. Kä llén BA, Otterblad Olausson P. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8.
23. Wogelius P, Norgaard M. Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4. (Pubitemid 44655607)
24. Ericson A, Kä llén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8. (Pubitemid 29446550)
25. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5. (Pubitemid 26338730)
26. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following firsttrimester exposure to fluoxetine (Prozac). JAMA 1993;269: 2246-8. (Pubitemid 23120281)
27. Gissler M, Teperi J, Hemminki E, Meriläinen J. Data quality after restructuring a nationwide medical birth registry. Scand J Soc Med 1995;23:75-80.
28. EUROCAT Guide 1.3 and reference documents. Instructions for the Registration and Surveillance of Congenital Anomalies. Available at: http://www.eurocat-network.eu/. Retrieved December 3, 2010.
29. National Institute for Health and Welfare. Congenital anomalies 1993-2008. Statistical Report 7/2011. Available at: http:// www.thl.fi/fi/ tilastot/epamuodostumat/. Retrieved April 19, 2011.
30. Pakkasjä rvi N, Ritvanen A, Herva R, Peltonen L, Kestilä M, Ignatius J. Lethal congenital contracture syndrome (LCCS) and other lethal arthrogryposes in Finland-an epidemiological study. Am J Med Genet A 2006;140A:1834-9.
31. Leoncini E, Botto LD, Cocchi G, Annerén G, Bower C, Halliday J, et al. How valid are the rates of Down syndrome internationally? Findings from the International Clearinghouse for Birth Defects Surveillance and Research. Am J Med Genet A 2010;152A:1670-80.
32. National Agency for Medicines (Department of safety and drug information) and Social Insurance Institution (Research department): Finnish Statistics on Medicines 2006. 1st ed. Edita Prima Oy, Helsinki (Finland); 2007.
33. Garne E, Khoshnood B, Loane M, Boyd P, Dolk H, EUROCAT Working Group. Termination of pregnancy for fetal anomaly after 23 weeks of gestation: a European registerbased study. BJOG 2010;117:660-6.
34. Sloot WN, Bowden HC, Yih TD. In vitro and in vivo reproduction toxicology of 12 monoaminergic reuptake inhibitors: possible mechanisms of infrequent cardiovascular anomalies. Reprod Toxicol 2009;28:270-82.
35. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003;21:417-24. (Pubitemid 37492996)
36. Kusakawa S, Yamauchi J, Miyamoto Y, Sanbe A, Tanoue A. Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci 2008;83:871-7.
37. Bosi G, Garani G, Scorrano M, Calzolari E, IMER Working Party. Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry. J Pediatr 2003;142:690-8. (Pubitemid 36737174)
38. Hoyme HE, May PA, Kalberg WO, Kodituwakku P, Gossage JP, Trujillo PM, et al. A practical clinical approach to diagnosis of fetal alcohol spectrum disorders: clarification of the 1996 institute of medicine criteria. Pediatrics 2005;115:39-47. (Pubitemid 43046280)
39. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group. Teratology 1999;60:33-6. (Pubitemid 29338853)